Business Context and Reporting Period
This Form 8-K Current Report was filed by iBio, Inc. on April 28, 2022. The report discloses the resignation of a senior executive and the subsequent appointment of a strategic advisor.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. The only financial data disclosed relates to executive compensation under a new agreement.
- Consultation Fee: $10,000 per month.
- Agreement Term: Initial period of twelve months, terminable by either party with or without cause after the initial term.
Material Changes
Executive Departure: Randy J. Maddux, Chief Operating Officer, resigned effective May 2, 2022. The resignation was not due to any disagreement with the Company.
Succession Plan: Mike Jenkins, Vice President of Operations, will assume Mr. Maddux's responsibilities.
New Arrangement: Mr. Maddux will transition to a strategic advisor role under a Consultation Agreement effective May 2, 2022.
Guidance, Outlook, and Risks
The filing contains no forward-looking guidance, financial outlook, or discussion of general business risks. The primary contingency noted is the transition of operational leadership and the ongoing financial obligation of the consultation agreement.
Investor Verification Checklist
- Verify the effective date of the COO resignation (May 2, 2022).
- Confirm the monthly compensation obligation of $10,000 for the strategic advisor role.
- Review the full text of the Consultation Agreement (Exhibit 10.1) for termination clauses and scope of services.
- Assess the impact of the leadership transition on ongoing operations under Mike Jenkins.